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Background: Pharmacy databases are commonly used to assess medication usage, and a number of measures
have been developed to measure patients’ adherence to medication. An extensive literature now supports these
measures, although few studies have systematically compared the properties of different adherence measures.
Methods: As part of an 18-month randomized clinical trial to assess the impact of automated telephone reminders
on adherence to inhaled corticosteroids (ICS) among 6903 adult members of a managed care organization, we
computed eight pharmacy-based measures of ICS adherence using outpatient pharmacy dispensing records
obtained from the health plan’s electronic medical record. We used simple descriptive statistics to compare the
relative performance characteristics of these measures.
Results: Comparative analysis found a relative upward bias in adherence estimates for those measures that require
at least one dispensing event to be calculated. Measurement strategies that require a second dispensing event
evidence even greater upward bias. These biases are greatest with shorter observation times. Furthermore, requiring
a dispensing to be calculated meant that these measures could not be defined for large numbers of individuals
(17-32 % of participants in this study). Measurement strategies that do not require a dispensing event to be
calculated appear least vulnerable to these biases and can be calculated for everyone. However they do require
additional assumptions and data (e.g., pre-intervention dispensing data) to support their validity.
Conclusions: Many adherence measures require one, or sometimes two, dispensings in order to be defined. Since
such measures assume all dispensed medication is used as directed, they have a built in upward bias that is
especially pronounced when they are calculated over relatively short timeframes (< 9 months). Less biased
measurement strategies that do not require a dispensing event are available, but require additional data to support
their validity.
Trial registration: The study was funded by grant R01HL83433 from the National Heart, Lung and Blood Institute
(NHLBI) and is filed as study NCT00414817 in the clinicaltrials.gov database.
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Pharmacy databases are increasingly being used to assess
medication usage, and a number of measures have been
developed to characterize both the intensity of medica-
tion usage compared to intended use (adherence), and
the extent to which such usage persists over time
(persistence) [1,2]. Such measures have strong appeal,
and an extensive literature now exists to support their
value in clinical research [3]. In particular, comparative* Correspondence: william.vollmer@kpchr.org
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reproduction in any medium, provided the oreffectiveness research increasingly depends on
pharmacy-based measures to assess both practice varia-
tions in prescribing, as well as health outcomes accord-
ing to therapeutic exposure in real-world, diverse patient
populations. Despite their increasingly widespread use,
however, relatively few studies have systematically com-
pared the properties of competing pharmacy-based mea-
sures of adherence [1,4-6].
One of the most widely cited pharmacy-based mea-
sures of medication adherence is calculated simply as
the total number of days of medication dispensed be-
tween some initial and final dispensing date divided by
the length of time between these dates. Steiner andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a larger class of measures they call continuous multiple-
interval measures of medication availability (or CMA
measures for short). They also define a related class of
measures they term continuous multiple-interval mea-
sures of medication gaps (or CMG measures) that at-
tempt to quantify theoretical gaps in medication usage.
CMA-based measures are easier to compute than CMG-
based measures and make no assumptions about pat-
terns of medication use, whereas CMG measures are
computationally more intensive and assume that medi-
cations, once dispensed, are used as directed.
Both CMA-based and CMG-based measures were ori-
ginally developed under the assumption that one has ac-
cess only to dispensing data during some defined
observation window and knows nothing else about the
individuals under observation. Possible refinements in-
clude (1) expanding the denominator to include the entire
observation window under study if it is known that the
individuals under study should be taking a given medica-
tion (e.g., by clinical practice guideline recommendation)
throughout the observation window and (2) accounting
for medications that individuals are known to possess at
the start of the observation window. The proliferation of
electronic medical records (EMRs) is making access to
such information increasingly more common.
We used data from an adherence trial among mem-
bers of a large health maintenance organization to com-
pare the properties and performance characteristics of a
variety of CMA- and CMG-based measures of medica-
tion adherence.
Methods
Study design and research setting
We report data collected as part of a randomized clinical
trial of members of the Northwest (KPNW) and Hawai‘iTable 1 Summary of study measures
Defn start of window to
first dispensing
last dispensing
to end of window
Timing^
CMA1 ignored ignored ignored
CMA2 ignored counted ignored
CMA3 ignored ignored ignored
CMA4 ignored counted ignored
CMA5 ignored ignored counted
CMA6 ignored counted counted
CMA7 counted counted counted
CMA8 counted counted counted
^refers to whether the timing of the dispensing (actual date dispensed) is taken int
#assumes medications taken as directed and new medications “banked” until neede
*lag refers to initial period covered by medication supply on hand at start of observ
counted starting with end of lag.(KPH) regions of Kaiser Permanente, a large, group-
model health maintenance organization. The main
results of the study have been presented elsewhere [8].
Participants were randomized to receive either usual
care or an 18-month intervention in which automated
telephone calls were used to promote improved adher-
ence to inhaled corticosteroids (ICS). The study was
approved by the Institutional Review Boards (IRBs) of
each region (Kaiser Permanente Northwest IRB, FWA
#00002344-00000405; and Kaiser Permanente Hawaii
IRB, FWA #00002344-00000402) and written informed
consent was waived. Research was carried out in compli-
ance with the Helsinki Declaration.
Kaiser Permanente provides comprehensive, prepaid
health care services to its members, and both KPNW
and KPH utilize a fully electronic medical record. An
end-user database captures diagnostic-specific utilization
data, procedures performed, new medication orders and
outpatient pharmacy dispensings.
Study population
The target population for the trial consisted of KPNW
and KPH members aged 18 and older who were mem-
bers for the 12 months prior to randomization, had been
seen for asthma and received at least one dispensing of a
respiratory medication during that timeframe. In order
to be able to study both primary and secondary ICS ad-
herence, the target population included individuals with-
out evidence of prior ICS use. The present analysis
focuses on the subset of 6903 individuals with ICS dis-
pensings during the baseline year.
Adherence measures
We compare eight alternative measures of adherence,
which we label CMA1-CMA8 (Table 1). Some of these
are classical CMA-type measures and some are derivedDescription of Measure
(# days dispensed, excluding last) / (first to last dispensing)
(# days dispensed, including last) / (first dispensing to end of window)
minimum (CMA1, 1)
minimum (CMA2, 1)
(# days theoretical use#) / (first to last dispensing)
(# days theoretical use#) / (first dispensing to end of window)
(# days theoretical use#) / (start to end of observation window),
includes in numerator meds carried into observation window
(# days theoretical use#) / (lagged* start of obs’n window to end of
window), numerator and denominator ignore intial lag period
o account in the calculations or is ignored.
d.
ation window. Medications dispensed during lag interval are “banked” and
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observation window, defined as the period from
randomization (t0) to end of follow-up (te). We also treat
all ICS medications, including combination agents con-
taining an ICS, as a single class of medications.
For any given participant, let t1, t2, . . ., tk be the dates
of the k ICS dispensing events that occurred during the
observation window, and n1, n2, . . ., nk be the corre-
sponding number of days of medication dispensed at
each timepoint. For any given dispensing event, we cal-
culated days' supply by dividing the number of puffs
per canister by the doctor’s suggested daily usage
instructions. Using this information, we define CMA1
as the total days’ supply of ICS dispensed between the
first and last dispensing event, excluding medications
dispensed at the final dispensing event, divided by
the elapsed time between these events. That is,
CMA1= (n1+ n2+ . . .+nk-1) / (tk – t1).
We shall refer to the denominator in these formulas,
in this case tk – t1, as the measurement window (i.e., the
subset of the larger observation window over which ad-
herence is actually calculated). Implicit in the use of the
above definition is the assumption that we don’t know
whether the participant should be taking the medication
of interest until we see a dispensing for it. That is why
the denominator starts with t1 rather than t0. Similarly
the dispensing at tk implies that the participant was still
taking the medication at time tk. However since we don’t
know if use of the medication was subsequently discon-
tinued under physician directions, observation stops at
tk rather than at te. Thus two dispensing events are
required to calculate the measure.
The first refinement to CMA1 tacitly assumes the
medication should continue to be taken during the inter-
val from tk to te (a period sometimes referred to as the
“terminal gap”) [9]. It is computed as the total days’ sup-
ply dispensed during the observation window, including
the medication dispensed at tk, divided by the time from
t1 to end of study: CMA2= (n1+ n2+ . . .+nk) / (te – t1).
In contrast to CMA1, CMA2 requires only one dis-
pensing event to be calculated. In the case of asthma, a
chronic condition for which ICS is considered first line
therapy, this assumption would seem to be reasonable,
especially if the observation window does not extend for
several years past tk. Because CMA1 and CMA2 may
both be greater than 1, some researchers prefer to cap
them at 1 (since nominally adherence shouldn’t be any
greater than 100 %). This gives rise to two additional
measures, CMA3=minimum (CMA1, 1) and CMA4=
minimum (CMA2, 1).
The terminology used to describe these measures in
the literature is not consistent. Hess et al. [1] refer to
CMA1 as the Compliance Rate and CMA2 as the Con-
tinuous Measure of Medication Acquisition. CMA3 andCMA4 appear to be examples of what Hess et al. refer
to as the Proportion of Days Covered, although it is not
clear from their description of this measure exactly what
denominator they use in this calculation, only that it is
capped at 1. In practice many authors also refer to both
CMA1 and CMA2 as the Medication Possession Ratio
(MPR), and indeed Hess et al. [1] note that at least four
different published measures have been ascribed this
name. By contrast they seem to use MPR (and equiva-
lently the Medication Refill Adherence percentage) to
refer to the total days’ supply divided by the entire obser-
vation window [i.e., (n1+ n2+ . . .+nk) / (te – t0)].
The preceding are all classical CMA-type measures in
that they do not account for the timing of the dispens-
ing events. An individual can have long gaps with no
medication dispensings and yet appear fully compliant
based on a large days’ supply dispensed toward the end
of the measurement window. The CMG-based measures
were developed to address this potential limitation. If
one assumes that all medication is taken exactly as
directed, then it is possible to determine those days for
which an individual is theoretically taking medication
and conversely those days for which no medication is
available and hence gaps in coverage exist. For instance,
if a participant receives a 30-day supply of ICS on day
10 of an observation window and another 30-day supply
on day 50, then he must have had a 10-day coverage
gap from days 40–49 if the medication was taken as
directed. In the event of overlapping dispensings, it is
conventional to assume that the new dispensing is not
started until the first is exhausted. Thus in the preced-
ing example if the second dispensing occurred on day
35, it would be “banked” and not started until day 40.
Traditionally, CMG measures are used to reflect the
proportion of measurement window in which medica-
tion is not taken and the duration of usage gaps, but
equivalently one can use 1-CMG to estimate the pro-
portion of days during a measurement window during
which a participant was taking medication. Similar to
the distinction between CMA1 and CMA2, we can
therefore define CMA5= (# adherent days between t1
and tk) / (tk-t1) and CMA6= (# adherent days between
t1 and te) / (te-t1).
That is, CMA5 ignores the last dispensing while
CMA6 does not. In both cases any unused medication
still available at the end of the observation window is
ignored in the calculations. Thus both measures are by
definition bounded above by 1 and hence along with
CMA3 and CMA4 are variants of Hess et al.’s [1] Pro-
portion of Days Covered measure, and also closely
aligned with what they term the Continuous Measure Of
Medication Gaps.
The definitions of CMA1-CMA6 are predicated on the
assumption that no other information is known about
Table 2 Comparison of distributional characteristics of
competing medication acquisition measures
CMA1 CMA2 CMA3 CMA4 CMA5 CMA6 CMA7 CMA8
N 4661 5716 4661 5716 4661 5716 6903 6903
Mean 0.61 0.63 0.55 0.52 0.54 0.50 0.36 0.35
Std Dev 0.94 1.52 0.29 0.31 0.29 0.30 0.30 0.30
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whether they should be taking ICS at the start of the ob-
servation window (and potentially if they are bringing
any unused medication into the start of the observation
window). This need not be the case. For instance, in our
study we had access to data from the EMR for the “base-
line” year prior to randomization. Given that we knew
each participant had a diagnosis of asthma and it was se-
vere enough to have been prescribed an ICS in the base-
line year, we felt it reasonable to assume that the
participant should be taking an ICS throughout the en-
tire 18-month follow-up window. Indeed the interven-
tion calls were intended in part to help restart ICS use
in those participants who had discontinued their use.
We therefore considered two additional CMG-based
measures.
CMA7 extends CMA6 by measuring adherence from
t0 rather than from t1 (that is, the measurement window
coincides with the observation window from t0 to te). In
addition, we adjusted the numerator to include any
medication still available based on the most recent dis-
pensing prior to randomization. Thus CMA7= (# adher-
ent days between t0 and te) / (te-t0). (Given the
assumptions we made about ICS use, it didn’t make
sense to consider an analog to CMA5 that only spanned
the interval t0 to tk.) Finally, since the initial adherence
resulting from medications already on hand at the start
of the intervention could not have been influenced by
our intervention, we considered one further refinement
to this definition, which was to start the observation
window on the day this initial prescription should have
been exhausted. If we label this date as t0*, we have
CMA8= (# adherent days between t0* and te) / (te-t0*).
The initial days’ supply on hand at the time of
randomization is not counted in the numerator and the
corresponding amount of time is also subtracted from
the denominator. An important feature of CMA7 and
CMA8 is that they do not require a dispensing during
the observation window to be calculated and hence can
be defined for all participants.Percentiles
min 0.02 0.01 0.02 0.01 0.02 0.01 0.00 0.00
1st 0.07 0.05 0.07 0.05 0.07 0.05 0.00 0.00
5th 0.12 0.09 0.12 0.09 0.12 0.09 0.00 0.00
25th 0.29 0.25 0.29 0.25 0.29 0.24 0.10 0.09
50th 0.51 0.48 0.51 0.48 0.51 0.45 0.29 0.27
75th 0.80 0.80 0.80 0.80 0.79 0.74 0.58 0.57
95th 1.24 1.33 1.00 1.00 1.00 1.00 0.95 0.95
99th 1.94 2.54 1.00 1.00 1.00 1.00 1.00 1.00
max 50.00 100.00 1.00 1.00 1.00 1.00 1.00 1.00
Medication acquisition reported as a fractional measure, e.g., 0.61 = 61 %.
Percentiles illustrate the medication acquisition distribution in each measure’s
population, e.g., the median for CMA1 = 0.51.Statistical methods
We use simple descriptive statistics to compare the per-
formance characteristics of these eight measures. For
some analyses we also calculate CMA measures, and
their associated statistics, for varying lengths of follow-
up (e.g., the first 3, 6, and 9 months of follow-up). We
limited these latter analyses to those individuals with
complete follow-up through 15 months (n = 4790,
69 % of the full cohort) to assure that any differences
were not attributable to patient mix. All statistical ana-
lyses were performed using SAS v9.1 (SAS Institute,
Cary, NC).Results
Summary descriptive statistics for the various adherence
measures are displayed in Table 2. As shown, the num-
ber of individuals for whom we can compute valid values
varies directly as a function of how these terms are
defined. CMA1, CMA3, and CMA5 all require the pres-
ence of two or more dispensings to be calculated, and
hence could be defined for only 68 % of the population.
CMA2, CMA4, and CMA6 require only a single dis-
pensing to trigger the calculation, and for our data could
be calculated for 83 % of the population. Finally, CMA7
and CMA8 are available for everyone since they require
no dispensings to calculate.
Table 2 also shows the relative upward bias in CMA1-
CMA6 (and especially CMA1 and CMA2) compared to
CMA7 and CMA8. Because CMA1 – CMA6 all require
at least one dispensing to be calculated, they by defin-
ition guarantee some level of adherence. This is not the
case for CMA7 and CMA8. The even more pronounced
relative upward bias in CMA1 and CMA2, which is
reflected in their means and standard deviations but not
their more robust interquartile ranges, results from
the extreme skewness in the right-hand tail of these
measures.
Although follow-up in these participants ranged from
1 to 18 months, the average duration of follow-up [mean
(SD)] was 15.1 (3.9) months. As shown in Table 3, which
presents data for only CMA4, CMA6, CMA7 and
CMA8, the upward bias associated with CMA1-CMA6
relative to CMA7 and CMA8 is even more pronounced
for shorter observation windows, but still persists even
when adherence is measured over a full 15 months. For
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with CMA1-CMA6 (or at least CMA4 and CMA6)
appears to largely disappear after 9 months. CMA7 and
CMA8 do not exhibit any evidence of a time bias, pre-
sumably since they don’t require an initial dispensing
(and its attendant implied adherence) to trigger the
calculation.
Discussion
While pharmacy-based dispensing records are becoming
increasingly popular tools for studying patterns of medi-
cation adherence, it is important to understand the po-
tential limitations of the resulting measures. By their
very definition, some measures of adherence are more
prone to an upward bias, while other potentially more
accurate measures may rely on a stronger set of assump-
tions to be valid. In addition, such pharmacy-based mea-
sures of adherence have face validity as measures of
actual medication usage only when measured over long
periods of time, since in this case high levels of esti-
mated adherence can only be achieved through repeated
refills (which tacitly implies ongoing medication usage).
Although our study was conducted in the context of a
randomized clinical trial, we believe our findings have
applicability to any pharmacoepidemiologic study that
might be conducted using electronic dispensing records.
One key consideration is that many of the commonly
used measures require medication use during the obser-
vation window in order to be calculated. Our study sug-
gests that this requirement will clearly bias adherence
values upwards, both by excluding the least adherent
patients and by building in a minimum level of adher-
ence in those who can be assessed. Increasingly, investi-
gators will have access to EMRs that can be used to
better define the population of individuals who are
known users of the medication of interest, or at least
have been prescribed such medications, thus allowing
more accurate assessments of adherence for a target
population. Further, EMR data can be used to identify
whether such medication use has been discontinued by
the patient’s provider. In this context it is therefore im-
portant to understand how many individuals are
excluded from your adherence estimates by various defi-
nitions, and our results show that this number can beTable 3 Impact of window length on measurement properties
Measure of Medication Aquisition
3 months 6 month
CMA4 0.68 ± 0.30 (6094) 0.58 ± 0.32 (
CMA6 0.65 ± 0.29 (6094) 0.53 ± 0.29 (
CMA7 0.42 ± 0.33 (6436) 0.41 ± 0.30 (
CMA8 0.35 ± 0.35 (6436) 0.38 ± 0.31 (
Data expressed as mean ± SD (sample size in parentheses).quite large. In the context of comparative studies, where
nonadherence can be differential across the groups being
compared, it is even more important to account for all
subjects.
Of the measures we studied, those that required an ini-
tial dispensing for their calculation, particularly if not
bounded above by 1 (i.e., CMA1-2), were prone to ex-
hibit an upward bias relative to the other measures we
considered. The four variants on the Proportion of Days
Covered, (CMA3-6), generally performed similarly to one
another. Adherence estimates based on all six of these
measures exhibited an increasingly upward bias with
shorter observation windows that did not flatten out
until after about 9 months of observation (Table 3). This
reflects the fact that the measurement window for all of
these measures begins with a dispensing, and hence a
certain amount of built-in implied adherence. The fact
that the measurement windows for CMA1, CMA3, and
CMA5 also all end with a dispensing event leads to a fur-
ther upward bias, since they effectively require that one
is actively using the medication throughout the measure-
ment window (or at least at both the beginning and end
of the window). However, use of CMA2, CMA4, and
CMA6 carry the implicit assumption that one should be
using the medication throughout the entire interval be-
ginning with the last dispensing event and extending
through the end of the observation window (i.e., tk to te).
If such an assumption is valid, then these measures
should yield more unbiased estimates of adherence than
those from their CMA1, CMA3, and CMA5 counter-
parts. They have the further added advantage that they
can be computed for more people since they only require
a single dispensing event to be defined. This is particu-
larly important since the missingness pattern will likely
not be random (that is, nonadherent individuals will be
more likely than adherent individuals to have missing
data). Thus the upward bias in CMA1, CMA3, and
CMA5 results both from a likely overestimation of ad-
herence in those for whom it can be calculated, as well as
from the fact that these same individuals are likely to be
selectively more adherent than those for whom these in-
dices cannot be calculated.
If viewed merely as measures of medication acquisi-
tion, rather than medication taking, some of theDuration of Observation Window
s 9 months 12 months 15 months
5545) 0.54 ± 0.32 (4915) 0.53 ± 0.31 (4045) 0.54 ± 0.31 (2694)
5545) 0.50 ± 0.29 (4915) 0.50 ± 0.29 (4045) 0.51 ± 0.29 (2694)
6185) 0.41 ± 0.29 (5855) 0.40 ± 0.29 (5355) 0.40 ± 0.29 (4485)
6185) 0.39 ± 0.30 (5855) 0.39 ± 0.29 (5355) 0.39 ± 0.29 (4485)
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CMA2 may be the preferred measures to use. Indeed
there may be some theoretical interest in those with very
high values for CMA1 or CMA2. However, values of
CMA1 or CMA2 greater than 1 can also substantially
skew mean rates of adherence upwards for a population
and in many if not most instances may not reflect actual
adherence behavior. To the best of our knowledge based
on a limited amount of data checking, the majority of
these extreme values reflect actual dispensings rather
than, for example, administrative errors in the data.
Whether they reflect excessive use by one individual,
medication sharing, vacation supplies, or medication
wastage we don’t know. Presumably these extreme
values reflect some combination of all of these possibil-
ities. In the end, however, we believe that most research-
ers who use these measures think of and talk about
them as measures of adherence, and for that reason we
would argue that CMA1 and CMA2 should not be used.
Nonetheless, further studies are needed to better under-
stand patient factors associated with very high rates of
dispensing, and whether such excessive dispensings are
associated with adverse health outcomes. Reasons for
this apparent over-adherence have been attributed to
changes in directions not noted in the pharmacy record,
intentional variable dosing, and stockpiling [10].
In practice, at least for our dataset, we found only min-
imal differences between CMA3/CMA4 and their CMG-
based counterparts CMA5/CMA6. Given that the latter
are computationally more intensive to calculate, this
might argue for the use of the former measures (which
are relatively easy to calculate). The main advantage of
using the CMG-based measures is their ability to de-
scribe gaps in medication use, although this requires the
rather strong assumption that the medication is used
exactly as directed. Nonetheless we feel that the added
benefit of studying gaps in usage conceptually has a lot of
appeal and is worth consideration when evaluating the
use of either CMA3 or CMA4 versus CMA5 or CMA6.
Each of CMA1 through CMA6 can be calculated
solely on the basis of pharmacy dispensing records avail-
able during the observation window. The use of CMA7
and CMA8 requires additional knowledge. This could
simply be information about medication use prior to the
start of the formal observation window of interest or, as
in our case, this information supplemented by diagnostic
data from an EMR. Due to the growing use of EMRs
and the expectation that they will only become more
prevalent over time, these requirements should not pose
a serious problem to the future use of these measures.
However, the availability of such information, while ne-
cessary, is not sufficient to justify the use of CMA7 or
CMA8. One must further be able to justify the assump-
tion that participants should be taking the medicationthroughout the observation window. The validity of this
assumption is likely to be more true for some medica-
tions than for others. In the case of asthma, for instance,
ICS are considered first-line therapy for patients with
persistent disease. Hence the presumption that a patient,
once prescribed them, should continue using them is
more likely to be true than not true (although physicians
may discontinue use if they are deemed ineffective for a
given patient). The presence of stop orders, if available
in the EMR, could be used to further refine the calcula-
tion of such measures, although our experience is that
clinicians are not good about documenting them.
The fact that CMA7 and CMA8 do not require a dis-
pensing during the observation window in order to be
calculated should, if the assumptions underlying their
use are met, cause them to lead to the most valid mea-
sures of adherence. However, given that the assumptions
for their use are inevitably not met for some individuals,
in practice population-based estimates of adherence
based on these measures are probably biased downwards
from truth. These observations are consistent with the
trends observed in our data, which showed both the
lowest estimates of adherence and the least change in
estimated adherence with varying length of the observa-
tion window. Even if the assumptions underlying CMA7
and CMA8 do lead to a downward bias in the estimates,
this needs to be weighed against the fact that these mea-
sures can be calculated for everyone. Despite the fact
that everyone had a pre-existing diagnosis of asthma and
an order or dispensing for ICS in the baseline year,
CMA1/3/5 could not be calculated for 32 % of this co-
hort, and even the less restrictive CMA2/4/6 measures
could not be calculated for 17 % of the cohort.
Although we did not evaluate them as part our ana-
lyses, under the assumptions for use of CMA7 and
CMA8 one could also modify the definitions of CMA4
and CMA6 to include the entire observation window in
the denominator. The modified CMA4 index in particu-
lar, which would correspond to Hess et al.’s [1] definition
of the Medication Possession Ratio, could be much more
easily computed than any of the CMG-based measures
and it is not unreasonable to hypothesize that it might
be fairly comparable in its measurement properties to
CMA7 and CMA8. It would also by definition be defin-
able for all subjects, and not just those with one or more
dispensing events during the observation window.
Our motivation for defining CMA8 is probably unique
to the context of randomized clinical trials, where the
concept of implied initial adherence at the start of an ad-
herence intervention that could not be related to treat-
ment allocation is a relevant consideration for analysis.
Our results are consistent with, and extend, the results
of previous investigations that have compared the per-
formance of competing measures of adherence in the
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though per their descriptions of them it is not clear that
these were all mathematically distinct measures. They
concluded that the equivalent of what we term CMA1-
CMA6 provided essentially the same adherence values,
although those measures that were capped at a
maximum value of 1 (or 100 %), similar to our CMA3-
CMA6 measures, produced adherence estimates that
were slightly lower than those that were not. Participants
in their study had a mean (SD) observation window of
350 (16) days, and they did not report on the impact of
using shorter observation windows. A separate review of
pharmacy-based measures of medication adherence,
however, noted that the assessment of adherence over
short intervals is likely to be imprecise and suggested
that the observation window should be long enough to
span the expected days’ supply from at least three
dispensing events [9]. This agrees well with our own ob-
servation (Table 3) that the extreme early bias in these
measures takes about 9 months to flatten out (the aver-
age ICS days’ supply for this population was 2–
3 months). Of course adherence often falls naturally over
time, particularly among new users [10] and that is
another rationale for prolonged observation of refill be-
havior. Vink et al. [11] compared the equivalents of our
CMA3 and CMA7 when assessed over one year and
concluded that the latter had a significantly better area
under the curve for classifying a measure of adherence
based on chart review.
Several reports have noted the lack of standardization
in terminology in the published adherence literature,
noting both that the same term (e.g., Medication Posses-
sion Ratio) can mean different things in different papers
and conversely that multiple distinct terms have been
used to describe the same measure [1,2,7,9]. These
reports also note that comparisons with published stud-
ies are further complicated by the fact that the precise
methodology used for defining a given measure is not
always provided. Our approach has been to explicitly de-
fine a series of measures and give their rationales and
assumptions for valid use, while avoiding assigning a for-
mal nomenclature to them. We have, however, tried to
relate our terms to those used by Hess et al. [1].
In the end, the choice of which adherence measure to
use for any given study must be based on the richness of
data available to the investigator, the chronicity of the
disease for which the medication is being used, the avail-
ability of other therapeutic options, knowledge about
standards of practice, and the question being addressed
by the study. No single measure is likely to be optimal
for all occasions. Still, given that the assumptions for use
of more sophisticated measures, such as CMA7 or
CMA8, are met, we believe our findings suggest that
these may be more appropriate (i.e., less biased andmore universally estimable) alternatives than simpler
measures such as the various derivatives of the MPR.
The study has two main limitations. First, none of the
measures described here really speak to the issue of pri-
mary nonadherence (failure to obtain the first fill of a
medication ordered by their clinician), and instead focus
on adherence among known medication users. Thus
from the perspective of overall population-based mea-
sures of adherence to prescribed medications, all of
these measures will tend to have a further upward bias.
In addition, we made no attempt to adjust for
hospitalization days in our adherence estimates. For
populations for which this is a meaningful consideration,
it is common to remove hospital days from the denomi-
nators of many of these statistics. However, for the
purpose of comparing relative properties of the various
measures, any bias this introduces is likely to be com-
parable across the measures so that relative comparisons
should be largely unaffected.
Conclusions
Estimates of medication adherence can vary markedly
among competing measures.
These differences are accentuated when adherence is
measured over relatively short timeframes (< 9 months).
Many commonly cited measures cannot be calculated
for large numbers of individuals because they require
one, or in some cases two, dispensings in order to be
defined. This leads to falsely optimistic estimates of ad-
herence. Less biased measurement strategies that do not
require a dispensing event to be calculated are available,
but require additional data to support their validity.
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